Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...

Full description

Bibliographic Details
Main Authors: Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff
Format: Article
Language:English
Published: PAGEPress Publications 2011-12-01
Series:Dermatology Reports
Subjects:
Basal cell carcinoma, vismodegib, basal cell nevus syndrome, hedgehog
Online Access:http://www.pagepress.org/journals/index.php/dr/article/view/3782

Internet

http://www.pagepress.org/journals/index.php/dr/article/view/3782

Similar Items